IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus
| Autor: | Chang Shu, Wenbo Huang, Yawei Fan, Yuan-Qin Min, Xizhong Jing, Wenjun Song, Huanliang Liu, Airu Zhu, Deyin Guo, Qi Cheng, Na Xu, Qing Guan, Yang Yu, Jincun Zhao, Daoyuan Yue, Ying Chen, Yingfang Liu, Meiqin Liu, Ping Lan, Xu Feng, Zifeng Yang, Dan Zhu, Jindong Zhao, Zhengli Shi, Fei Deng, Xiaoping Chen, Huanhuan Liang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
viruses
Cell Article influenza virus General Biochemistry Genetics and Molecular Biology Virus Mice Influenza Human medicine Animals Humans Macrophage Neutralizing antibody Lung IFP35 Inflammation Mice Knockout biology SARS-CoV-2 business.industry Macrophages Mortality rate Intracellular Signaling Peptides and Proteins Patient Acuity COVID-19 virus diseases biomarker and therapeutic target medicine.disease Antibodies Neutralizing COVID-19 Drug Treatment Mice Inbred C57BL Disease Models Animal medicine.anatomical_structure cytokine storm Immunology biology.protein Biomarker (medicine) Cytokine storm business Biomarkers |
| Zdroj: | Cell Reports |
| ISSN: | 2211-1247 |
| Popis: | Previous studies showed that the high mortality caused by viruses such as SARS-CoV-2 and influenza virus, primarily results from the complications of a cytokine storm. Therefore, it is critical to identify the key factors participating in the cytokine storm. Here, we demonstrate that the interferon-induced protein 35 (IFP35), plays an important role in the cytokine storm induced by SARS-CoV-2 and influenza virus infection. We find that the levels of serum IFP35 in SARS-CoV-2 patients correlates with the severity of the syndrome. Using mouse model and cell assays, we show that IFP35 is released by lung epithelial cells and macrophage after SARS-CoV-2 or influenza virus infection. In addition, we show that administration of neutralizing antibody against IFP35 considerably reduce lung injuries, and thus the mortality rate of mice exposed to viral infection. In conclusion, our findings suggest that IFP35 serves both as a biomarker and a therapeutic target in virus-induced syndromes. Graphical Abstract Yu et al. identify IFP35 both as a biomarker and a therapeutic target in SARS-CoV-2 or influenza virus induced syndromes. Neutralizing antibody against IFP35 considerably reduces lung injury and the mortality of infected mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|